Edetate disodium MedWatch alert
Executive Summary
FDA advising hospitals to evaluate need to keep Edetate Disodium stocked and consider removing it from shelves to avoid confusion with similarly named Edetate Calcium Disodium. Edetate Disodium is approved to treat patients with hypercalcemia or digitalis in the blood while Edetate Calcium Disodium is approved to treat severe lead poisoning, but both products are used off-label as chelators and use the same abbreviation. The agency issues a public health advisory for Hospira's Endrate and generics Jan. 18 because of several fatalities caused by confusion of the drug names...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.